PMID: 25743134Mar 7, 2015Paper

Treatment with carbon-ion radiotherapy and its combinations -- basic biological studies and investigations at the National Institute of Radiological Sciences

Gan to kagaku ryoho. Cancer & chemotherapy
Takashi Imai

Abstract

The clinical application of carbon ions generated by the heavy ion medical accelerator in Chiba (HIMAC) reached its 20th anniversary in 2014. More than 9,000 cancer patients have been treated at the National Institute of Radiological Sciences (NIRS). Carbon-ion radiotherapy has been applied for treating various types of tumors that were considered difficult to control with existing modalities. Our experience to date has indicated that carbon-ion radiotherapy is advantageous for head and neck cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, bone/soft tissue sarcomas of the pelvis, uterine cervix adenocarcinomas, and other cancers. However, some cancer types (such as those in close proximity to radiosensitive normal organs) require additional treatments to sensitize the target cancer because of limitation of the irradiation dose. Furthermore, systemic combined therapy is also utilized to suppress possible metastasis. Currently, some anticancer agents are utilized with carbon-ion radiotherapy, including dacarbazine, nimustine hydrochloride, vincristine (DAV), gemcitabine, cisplatin, and 5-fluorouracil. Interesting reagents such as PARP and HSP90 inhibitors have been proposed as cancer cell- specific sensitiz...Continue Reading

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
Jun-ichi Saitoh, Takashi Nakano
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Hirohiko TsujiiTadaaki Miyamoto
© 2022 Meta ULC. All rights reserved